# Moderna Q3 2026 Earnings Beat

> Moderna's Q3 2026 earnings beat estimates with $0.38 EPS and 29% revenue growth.
- Title: Moderna Q3 2026 Earnings Beat | Shortify
- Summary: Moderna's Q3 2026 earnings beat estimates with $0.38 EPS and 29% revenue growth.
- Keywords: moderna, q3 2026, eps, revenue, net margin, biotech, vaccines, respiratory vaccines, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/moderna-q3-2026-deep-dive-eps-beats-estimates-revenue-up-29
- Author: AlphaStreet Newsdesk
- Published: 2026-11-06T17:28:50+00:00
- Read time: 1 min
- Topics: moderna, q3 2026, eps, revenue, net margin, biotech, vaccines, respiratory vaccines
## Q3 2026 Results
Moderna delivered GAAP EPS of $0.38 against expectations for a $1.28 loss.
## Revenue Growth
Revenue reached $1.31 billion, up 29.0% year-over-year.
## Net Margin Shift
Net margin swung from -19.6% to 12.4% year-over-year.
## Operating Profit
Operating income of $130.0 million with 9.9% margin.
## Seasonal Volatility
Q3 revenue surge follows Q2 trough due to respiratory vaccine cycles.
## Capital Raise
Raised $3 billion through 0% convertible note debt.
## Stock Reaction
Stock dropped 6.5% to $241.46 despite earnings beat.
## What to Watch
Q4 results will determine if profitability sustains through seasonal cycles.
## Key takeaway

Moderna returned to profitability in Q3 2026 with $1.31B revenue and 12.4% net margin after a year-over-year loss.